Advertisement
Advertisement
U.S. Markets open in 3 hrs 44 mins
Advertisement
Advertisement
Advertisement
Advertisement

Isleworth Healthcare Acquisition Corp. (ISLE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.90+0.01 (+0.15%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.89
Open9.90
Bid9.88 x 1100
Ask9.95 x 1200
Day's Range9.90 - 9.91
52 Week Range9.66 - 9.94
Volume6,010
Avg. Volume45,106
Market Cap259.424M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Cytovia Therapeutics to Present In Vivo Multiple Myeloma Data of its CD38-Targeting Flex-NK™ Cell Engager at EHA 2022 Congress

    Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the the Annual European Hematology Association's (EHA) 2022 Hybrid Congress, taking place June 9 – 12, 2022 at the Messe Wien Exhibition and Congress Center in Vienna, Austria, and online.

  • PR Newswire

    Cytovia Therapeutics to Present at AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer

    Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells to fight cancer through multispecific antibodies and stem cell engineering, announced today that it will be presenting at the AACR Special Conference on Advances in the Pathogenesis and Molecular Therapies of Liver Cancer, to be held from May 5-8, 2022, at the Westin Copley Place in Boston, Massachusetts. The conference is an in-person event and will not

  • Benzinga

    Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut

    About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ: CLLS), Cytovia plans to list on NASDAQ via a merger with the SPAC Isleworth Healthcare Acquisition Corp (NASDAQ: ISLE). The company went on to create a China joint venture. The biotech teamed up with China-based biotech investor TF Capital to form CytoLynx Therapeutics with $45 million in funding in September 2021. Related: Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China. The blank-

Advertisement
Advertisement